Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Janssen stops Phase 3 trial testing high-dose Opsumit in CTEPH

A Phase 3 clinical trial testing high-dose Opsumit (macitentan) in people with chronic thromboembolic pulmonary hypertension (CTEPH) has ended early after an analysis showed the treatment is unlikely to help patients. The announcement was made in a press release from Janssen, the company that markets Opsumit. Opsumit…

Tenax receives patent for TNX-103, oral levosimendan, for PH-HFpEF

Tenax Therapeutics has been issued a U.S. patent covering oral levosimendan, also known as TNX-103, for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The patent (U.S. Patent No. 11,701,355) is expected to provide intellectual property protection for TNX-103 through December 2040.

Liquidia licenses rights in North America to inhaled L606 for PH

Liquidia has licensed the rights in North America to L606, a novel inhaled formulation of treprostinil that’s being tested in trials of people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). “L606 is the perfect life-cycle complement to our pipeline and…

Janssen seeks approval in Europe for PAH combination therapy tablet

Janssen Pharmaceuticals has submitted an application in Europe asking regulatory authorities to approve the company’s combination therapy of macitentan and tadalafil — developed as a single tablet — for pulmonary arterial hypertension (PAH). The filing comes less than a month after Janssen submitted a similar application seeking approval…

More than 50% of preterm babies with PH respond to Revatio: Study

Treatment with intravenous Revatio (sildenafil) can improve oxygen delivery and heart health in some premature babies with pulmonary hypertension, although more than four in 10 patients don’t respond to it. “Our study adds new insights on preterm and [very low birth weight]-infants with sildenafil treatment for primary early PH…

Better ways sought to gauge patients’ experiences in PAH trials

The outcomes used in clinical trials of pulmonary arterial hypertension (PAH) don’t fully reflect the priorities of patients and clinicians, a new study asserts. The study, “‘It’s that invisible illness’: Patient and clinician perspectives on outcomes in pulmonary arterial hypertension treatment,” was published in the journal…

Janssen asks FDA to approve macitentan, tadalafil combo tablet

Janssen Pharmaceuticals has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of a combination tablet containing both macitentan and tadalafil as a treatment for pulmonary arterial hypertension (PAH). “People with PAH are often prescribed numerous medicines to manage their condition, so the potential…

Inhaled imatinib treatment found safe in healthy people in study

Treatment with AER-901, an inhaled formulation of imatinib that Aerami Therapeutics is developing as a treatment for two forms of pulmonary hypertension, was generally well-tolerated in a Phase 1 study conducted with healthy volunteers. That’s according to safety data presented by Aerami at the 2023 American Thoracic Society…

KER-012 reduces markers of heart damage, fibrosis in Phase 1 study

Treatment with KER-012, an experimental therapy Keros Therapeutics is developing to treat pulmonary arterial hypertension (PAH), lowered markers of heart damage, fibrosis, and inflammation in a Phase 1 clinical trial that tested the therapy in healthy postmenopausal women. Keros presented the findings at the American Thoracic Society (ATS)…


A Conversation With Rare Disease Advocates